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Objectives: The Society for Vascular Surgery Outcomes Committee, including ad hoc members from Society of Thoracic
Surgeons, AmericanAssociation of Thoracic Surgery, and Society for Interventional Radiology, collected outcomes of patients
with traumatic thoracic aortic transections treated with endovascular grafts. Results through 1 year of follow-up are reported.
Methods: Data from five physician-sponsored investigational device exemption clinical trials from 2000 to 2008 were
entered using standardized forms and definitions. Adverse events were reported early (<30 days) and late (>30 days) by
body system. Major adverse events included one or more of the following: death, stroke, myocardial infarction, renal
failure, respiratory failure, paralysis, or bowel ischemia.
Results:Therewere 60 symptomatic patients (68.3%men;mean age, 46 years)with traumatic aortic transections, ofwhich 97%
were due to amotor vehicle accident and 3%were related to other blunt trauma. The average total injury severity score was 39,
mostwith involvement of the chest and abdomen.The average surgical timewas 125minutes. Themeanhospital length of stay
was 17 days. Associated procedures for the management of nonaortic injuries occurred in 51.7%. All-cause mortality was 9.1%
at 30 days and 14.4% at 1 year. One or more major adverse events occurred in 23.3% of the patients, major adverse events
occurred early in 20.0% and late in 3.6%. Death accounted for 41.7% of the early and all of the late major adverse events. Early
adverse events included 16.7% pulmonary, 13.3% neurologic, and 11.7% vascular complications. Late adverse events included
one patient (1.8%) with pulmonary failure and one patient (1.8%) who died of an unknown cause.
Conclusions: One-year results of endograft placement for the management of patients with traumatic aortic injury are
acceptable. Most cases treated were due to motor vehicle accident and associated with multiple coexisting injuries. Approxi-
mately three-quarters of the deaths occurred<30 days, indicating the acute severity of the condition. Although the relatively
low rates of adverse andmajor adverse events are consistent withwhat is anticipated in an otherwise healthy population, future
device and procedural developments may facilitate improved outcomes in the future. (J Vasc Surg 2011;53:1091-6.)
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0Traumatic aortic injury is associated with instantaneous
death or complex treatment algorithms should the patient
survive to hospitalization. The advent of endovascular devices
for the thoracic aorta has added additional treatment options.
The Society for Vascular Surgery Outcomes Committee, in-
cluding ad hoc members from the American Association for
Thoracic Surgery, Society of Thoracic Surgeons, and Society
for Interventional Radiology, report 1-year outcomes in trau-
matic aortic transection patients treated with thoracic endo-
vascular aortic repair (TEVAR). This database serves as a
performance goal in establishing objective performance
criteria for evaluating new thoracic endovascular devices in
the treatment of transections based on data from physician-
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The catastrophic thoracic aortic indications database
ncludes specific patients who sustained traumatic thoracic
ortic injury, transection, or rupture. Although each
S-IDE clinical trial used separate protocols, eligibility
riteria, and different thoracic aortic endovascular grafts,
ata for this database were collected using standardized
efinitions and case report forms. Data were collected from
rocedures performed between 2000 and 2008. Adverse
vents are reported early (30 days) and late (30 days) by
ody system. Major adverse events include one or more of
he following: death, stroke, myocardial infarction, renal
ailure, respiratory failure, paralysis, or bowel ischemia.
Recorded data include baseline (preoperative) informa-
ion such as demographics, medical history, and transection
tiology and injury score; procedural information, including
echnical success and intraoperative and predischarge compli-
ations, as well as follow-up information such as postoperative
ortality, stroke, myocardial infarction, and other morbidi-
ies. All analyses performed included only deidentified and
ggregated data without TEVAR device-specific information.
Statistical methods. Descriptive statistics are listed as
ean  standard deviation for continuous variables and
ercent (frequency) for categoric variables. Kaplan-Meier
ethods were used to obtain survival estimates for 30 days,
months, and 1 year. NERI performed all statistical anal-
ses using SAS software (SAS Institute, Cary, NC).
ESULTS
The five clinical centers reported 60 symptomatic transec-
ion patients (68.3% male). The demographics, medical and
urgical histories, and baseline characteristics are presented in
able I. The average patient age was 46 years, and 28.3% were
ged55 years. The most prevalent comorbidities were cur-
ent or past smoking (72.1%) and hypertension (25.0%). The
able I. Continued
TT
aseline characteristicsa (n  60)
espiratory status
Intubated 55.0 (33/60)
Distressed 1.7 (1/60)
Stable 43.3 (26/60)
esuscitation at presentation/baseline
Crystalloid, mL 678.6  1280.62
Packed RBC, unit 1.2  2.87
Fresh frozen plasma, units 0.6  2.80
Platelets, packs 4.8  34.74
Inotropes 3.4 (2/58)
BI, Ankle-brachial index; COPD, chronic obstructive pulmonary disease;
BP, diastolic blood pressure; PTCA, percutaneous transluminal coronary
ngioplasty; RBC, red blood cells; SBP, systolic blood pressure.
Continuous data are presented as mean  standard deviation; categoric
ata as percentage (number).Table I. Baseline demographics, history, and
characteristics of patients with thoracic transection (TT)
TT
Baseline characteristicsa (n  60)
Demographics
Age, years 46.5  17.99
Male gender 68.3 (41/60)
White race 76.7 (46/60)
Hispanic ethnicity 25.0 (15/60)
Medical history
Diabetes 5.0 (3/60)
Cancer 1.7 (1/60)
Liver disease 3.3 (2/60)
Cerebrovascular accident 1.7 (1/60)
Transient ischemic attack 0.0 (0/60)
Paralysis/paraparesis 0.0 (0/60)
COPD 5.0 (3/60)
Other chronic pulmonary disease 5.0 (3/60)
Congestive heart failure 0.0 (0/60)
Hypertension 25.0 (15/60)
Myocardial infarction 1.7 (1/60)
Arrhythmia 1.7 (1/60)
Connective tissue disorder 0.0 (0/60)
Vascular disorders 5.0 (3/60)
Genitourinary/renal disorders 3.3 (2/60)
Smoking history
Current smoker 39.5 (17/43)
Prior history 32.6 (14/43)
Never smoked 27.9 (12/43)
Surgical history
Coronary artery bypass grafting 1.7 (1/60)
PTCA and/or coronary stent 0.0 (0/0)
Carotid endarterectomy or stent 0.0 (0/60)
Other aortic surgeries 1.7 (1/60)
Mechanical ventilation for 24 hours 0.0 (0/60)
Non-cardiac thoracic 0.0 (0/60)
Cardiac valve replacement 1.7 (1/60)
Pacemaker 0.0 (0/60)
Peripheral vascular 0.0 (0/60)
Dialysis 3.3 (2/60)
Other 13.3 (8/60)
Renal function test and vital signs
Creatinine, mg/dL (n  54) 0.9  0.77
SBP, mm Hg (n  54) 124.0  16.18
DBP, mm Hg (n  54) 63.5  13.12
ABI, left (n  4) 1.0  0.12
ABI, right (n  4) 1.0  0.02
Pulse evaluation, % present
Radial
Right 95.2 (20/21)
Left 90.5 (19/21)
Femoral
Right 86.7 (13/15)
Left 86.7 (13/15)
Popliteal
Right 88.2 (15/17)
Left 88.2 (15/17)
Dorsalis
Right 97.1 (34/35)
Left 97.1 (34/35)
Post-tibial
Right 94.7 (18/19)
Left 94.7 (18/19)
Hemodynamic status
Critical: SBP 90 mm Hg 5.1 (3/59)
Guarded: SBP 90 mm Hg w/support 18.6 (11/59)ack of other diseases coexisting with similar frequencies in this
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Volume 53, Number 4 Dake et al 1093patient population underscores the relatively healthy disease
profile of this group. The mean ankle-brachial indices were 1.0
bilaterally. At the time of initial medical examination after
transection, 76.3% of the patients were considered stable
hemodynamically, 18.6% were guarded, and 5.1% were critical
(Table I). Conversely, 43.3% were judged to have a stable
respiratory status, 55.0% required intubation and mechanical
ventilatory support, and in 1.7%, respiration was deemed
distressed. As a part of preoperative resuscitation efforts, intra-
venous crystalloid therapy (mean volume, 679 mL) was ad-
ministered. Parenteral inotropic support was provided in
3.4%.
Motor vehicle accidents were responsible for 96.7% of the
injuries, and blunt trauma caused the remaining 3.3%. Details
of the preoperative trauma evaluation performed at the initial
hospital assessment are presented in Table II. The mean injury
severity score was 39, with a scale maximum of 75. The chest
(4.4) and the abdomen (3.9) had the highest Associated
Injury Scale scores of a possible 6, which represents the most
severe injury involving one of the prespecified body catego-
ries. Clinical utility measures are presented in Table III. Ap-
proximately 86.4% of patients had an American Society of
Anesthesiologists grade3 (47 at grade 4; 4 at grade 5), and
about 13.6% had3 (1 at grade 1; 2 at grade 2; 5 at grade 3).
TEVAR occurred on the day of hospital admission in 51% of
the patients, 8% underwent the procedure between 24 and 48
hours of hospitalization, and 1% at between 48 and 72 hours
after admission. Delay in treatment beyond the initial admis-
sion was due to stabilization of the patient and treatment of
other life-threatening injuries.
An average of one stent graft was implanted. All devices
were deployed successfully without technical difficulties. The
mean length of the deployed prostheses was 127  27 mm.
During the procedure, intentional stent graft coverage of the
left subclavian artery occurred in 8%. The mean surgical time
was 125 minutes, with a mean estimated blood loss of 198
mL. The average hospital length of stay was 17 days.
Outcomes at 30 days. By the 30-day follow-up, 10.5%
Table II. Preoperative presentation of patients with
thoracic transsection (TT)
TT
Preoperative presentationa (n  60)
Etiology
Motor vehicle accident 96.7 (58/60)
Other blunt trauma 3.3 (2/60)
Associated Injury Scale scores
Head and neck (n  27) 3.3  1.44
Face (n  15) 2.3  1.11
Chest (n  52) 4.4  0.86
Abdomen (n  36) 3.9  1.20
Extremity (n  30) 3.0  1.20
Injury severity score (n  60) 39.1  20.04
Associated procedures 51.7 (30/58)
aCategoric data are presented as percentage (frequency); continuous data as
mean  standard deviation.(4 of 38) of the patients had required a secondary procedure io manage associated nonaortic conditions unrelated to the
EVAR procedure or the endovascular graft. No secondary
pen or endovascular aortic interventions were performed
30 days of the primary TEVAR procedure.
Most of the adverse events observed by 30 days were
ulmonary (16.7%), neurologic (13.3%), and vascular (11.7),
s detailed in Table IV. At least one early major adverse event
ccurred in 20% of the patients, with 8.3% mortality. Vascular
ccess complications occurred in 11.7%, including two pa-
ients with migration during ballooning, two with infolding of
he stent graft, two with endoleak, and one with thrombosis.
ll major adverse events are presented in Table V. The 30-day
aplan-Meier estimate for mortality was 9.1%, as illustrated in
he Fig. These deaths represent most of the deaths that oc-
urred within the 1-year follow-up period.
Outcomes at 1 year. At the end of 1 year of clinical
ollow-up, no additional secondary procedures were re-
orted. Two additional deaths were reported between 31
nd 365 days, one patient died of respiratory failure and
ne without a known cause. The 1-year Kaplan-Meier
oint estimate for mortality was 14.4% (Fig). Aside from
he initial dip due to early mortalities 30 days after the
raumatic injury, the survival curve remained stable for the
emainder of the 1-year follow-up (Fig).
ISCUSSION
Standard treatment of patients with thoracic aortic
ransections has been early open surgical repair with graft
able III. Clinical utility, procedural, and predischarge
f patients with thoracic transection (TT)
TT
ariablea (n  60)
SA grade
3 13.6 (8/59)
3 86.4 (51/59)
urgery, min (n  55) 125.1  79.97
ospital length of stay, days 17.4  18.56
stimated blood loss, mL (n  54) 197.6  176.34
tent grafts, No. 1.1  0.30
ength of grafts, mm 127.3  26.58
dditional procedures 20.0 (12/60)
liac conduit, before deployment 1/12
ubclavian coverage
Predeployment 1/12
Postdeployment 5/12
arotid-subclavian bypass, postdeployment 1/12
ncovered aortic stent, pre-/postdeployment 0/12
em-fem bypass, postdeployment 1/12
ther
Predeployment 1/12
Postdeployment 5/12
tent graft deployed without difficulty 100.0 (60/60)
dverse events
During procedure 6.7 (4/60)
Predischarge 61.7 (37/60)
SA, American Society of Anesthesiologists.
Categoric data are presented as percentage (frequency); continuous data as
ean  standard deviation.nterposition. More recently, pharmacologic lowering of
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namics have facilitated stabilization of patients and the
opportunity for delayed repair, but the ongoing risk of
catastrophic rupture and the persistently high postoperative
mortality rates reported in recent studies make a less inva-
sive alternative attractive for immediate repair of patients
Table IV. Early and late adverse events
0-30 days 31-365 days
(Early) (Late)
Event % (No.) % (No.)
Bleedinga 5.0 (3/60) 0.0 (0/55)
Cardiacb 10.0 (6/60) 0.0 (0/55)
Gastrointestinal 0.0 (0/60) 0.0 (0/55)
Genitourinary 0.0 (0/60) 0.0 (0/55)
Infectionc 3.3 (2/60) 0.0 (0/55)
Neurologicd 13.3 (8/60) 0.0 (0/55)
Orthopedice 10.0 (6/60) 0.0 (0/55)
Pulmonaryf 16.7 (10/60) 1.8 (1/55)
Renalg 5.0 (3/60) 0.0 (0/55)
Vascularh 11.7 (7/60) 0.0 (0/55)
Wound 0.0 (0/60) 0.0 (0/55)
Otheri 10.0 (6/60) 0.0 (0/55)
Unknownj 0.0 (0/60) 1.8 (1/55)
aBleeding includes heparin-induced thrombocytopenia, retroperitoneal he-
matoma.
bCardiac includes angina, chest pain, arrhythmia, myocardial infarction,
cardiac arrest/tamponade, diabetes mellitus.
cInfection includes increased white blood count, sepsis.
dNeurologic includes cerebrovascular accident, lumbar plexopathy, memory
loss, depression, quadripareses.
eOrthopedic includes fractures.
fPulmonary includes respiratory distress, respiratory failure, pneumonia,
pleural, effusion, prolonged ventilator support.
gRenal includes urinary tract infection, increased creatinine, chronic renal
insufficiency or failure requiring dialysis.
hVascular includes migration, endoleak, deep vein thrombosis, pulmonary
embolism, stent graft infolding.
iOther includes motor vehicle accident injuries, allergic rash.
jUnknown is unknown cause of death.
Table V. Early and late major adverse events (MAEs)
0-30 days 31-365 days
(Early) (Late)
Event % (No.) % (No.)
Patients with 1 MAE 20.0 (12/60) 3.6 (2/55)
Death 8.3 (5/60) 3.6 (2/55)
Myocardial infarctiona 0.0 (0/60) 0.0 (0/55)
Cerebrovascular accidentb 10.0 (6/60) 0.0 (0/55)
Renal failurec 0.0 (0/60) 0.0 (0/55)
Respiratory failured 3.3 (2/60) 0.0 (0/55)
Paralysis/paraparesise 1.7 (1/60) 0.0 (0/55)
Bowel ischemiaf 0.0 (0/60) 0.0 (0/55)
aMyocardial infarction is defined as Q-wave and non-Q-wave ischemia.
bCerebrovascular accident is defined as thrombotic or hemorrhagic stroke;
excludes transient ischemic attack.
cRenal failure is defined as requiring dialysis; excludes renal insufficiency.
dRespiratory failure is defined as requiring ventilatory support; excludes
chronic obstructive pulmonary disease or pulmonary complications.
eParalysis/paraparesis is defined as spinal cord injury score of 0 to 4.
fBowel ischemia is defined as mesenteric ischemia or ischemic colitis.with polytraumatic injuries.1-8 lDespite important improvements in the initial manage-
ent of traumatic injuries, open surgical techniques, and
ostoperative critical care, the mortality rate is 15% to 40% in
ost series.1-11 In many cases, the poor outcome after open
urgical repair may be secondary to coexisting associated inju-
ies; however, the requirements for left thoracotomy and risks
f systemic heparinization, aortic cross-clamping, and single-
ung ventilation can contribute to considerable morbidity,
ncluding hemorrhage, spinal cord ischemia (range, 3%-
6%),1-11 and prolonged respiratory insufficiency and infec-
ious complications (range, 24%-65%) in the presence of lung
ontusions and rib fractures.1-8,10
This observational study presents prospectively collected
ata from five centers with U.S. Food and Drug Administra-
ion-sanctioned IDE studies of TEVAR, and to our knowl-
dge, it is the largest series of transection patients managed by
mmediate endovascular repair with follow-up of 1 year. The
ature of the required regulatory reporting resulted in similar
easurements of outcomes and relatively uniform data sets in
omposition and structure reported by each site and provides
n opportunity to evaluate the longer-term outcomes in pa-
ients beyond the immediate procedural results.
The mean length of endografts was 127 mm, the mean
rocedural time was 125 minutes, and in 8% (5 of 60) of
ases, the left subclavian artery was intentionally covered by
he prosthesis and carotid-subclavian bypasses were not
erformed. It is interesting that two of five patients
40%) with subclavian coverage experienced a cerebro-
ascular accident 30 days. This finding raises the issue
egarding left subclavian artery (LSA) revascularization
efore TEVAR, as recommended in the recent Society for
ascular Surgery (SVS) Practice Guidelines.12 Most of
hese cases are emergent procedures and correspond to the
ualifying statement in the guidelines document, which
akes an exception to this recommendation when preop-
rative LSA revascularization may be precluded in emer-
ent procedures. In light of the recommendation, consid-
ration for LSA bypass in traumatic aortic injuries may be
easonable if time constraints and associated patient injuries
ermit. The frequency of LSA coverage is comparable with
ublished reports.9,11,13,14
The mean hospital length of stay in this study group
as 17 days. This is less than the averages of 21 days
ublished in a multicenter transection series of 125 TEVAR
ases10 and 29 days reported in a meta-analysis encompass-
ng 262 endograft repairs of transection.15 As previously
etailed in other accounts, the need to address nonaortic
njuries was high: 52% of the patients in this series required
n associated procedure.9-11,13-18
The all-cause mortality at 30 days was 9.1%, which is
ithin the reported range of 0% to 17.9%.9-13,19 Similarly, the
elatively low frequency of paraplegia/paraparesis, 1.7% in our
xperience, is in line with published TEVAR results and less
han that established for open repair of transection. Indeed, a
arge meta-analysis of contemporary publications addressing
ransection estimates that TEVAR reduces the risk of paraple-
ia by 70%. In addition, the article by Xenos et al18 calcu-
ates a similar reduction in procedure-related mortality with
t
a
r
1
a
r
r
e
t
b
a
w
s
d
l
i
f
T
t
f
tality
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 4 Dake et al 1095TEVAR and 50% reduction in 30-day mortality relative
to open surgery. Other meta-analyses have reached similar
conclusions regarding a reduction of mortality and morbid-
ity with TEVAR management of transection.15,16
After 1 year of follow-up, the cumulative mortality in our
series was 14.4%. Although most published studies have not
reported outcomes at 1 year after repair, those that have
detailed late results present similar survival values with rela-
tively stable late mortality rate after hospital discharge.13,15,16
One interesting finding in our study was that no additional
procedures were required after discharge, although radiologic
imaging was not included. No secondary interventions were
documented after hospital discharge through the first year of
clinical follow-up. This plus the absence of any early or late
conversion events are distinct, and if confirmed by further
studies, may differentiate endovascular therapy for transection
from the published outcomes of TEVAR for the management
of less focal aortic pathologies, such as degenerative descend-
ing aneurysms and aortic dissections.20-24
Adverse events were common in our experience and af-
fected most organ systems. The range and frequency of com-
plications, however, is no different than those that have been
reported for TEVAR treatment of a variety of aortic patholo-
Fig. Kaplan-Meier survival curve of all-cause morgies, including experience with the management of transec- aion.9-24 Most periprocedural adverse events were pulmonary
nd neurologic complications that occurred in 17% and 13%,
espectively, and vascular access complications occurred in
1.7%.
These untoward events are routinely cited in reports of
ortic endografting, but the frequency of vascular injury
elated to the introduction of the device is less than the
ange of 20.0% to 22.5% observed for other thoracic aortic
ndograft applications.20-24
The less frequent occurrence of vascular access complica-
ions in these patients with traumatic aortic transections may
e related to management of affected patient populations that
re younger (mean age, 46 years; 72% of patients age 55)
ith less diseased iliac and femoral conduit vessels, as well as
maller aortas that enable smaller diameter grafts systems to be
elivered to the thoracic target. All of these factors would
essen the risk of vascular injury during TEVAR.
It is also worth commenting on the risk of spinal cord
schemic events associated with TEVAR. Although the
requencies of paraplegia and paraparesis are lower with
EVAR than with open repair of traumatic aortic transec-
ion,10,13,15,16,18 they are also lower than those reported
or TEVAR of other aortic lesions, such as descending
for 60 patients with traumatic aortic transection.neurysms.20-24 Temporary interruption of perfusion to
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repair and systemic hypotension that may complicate tho-
racotomy have been implicated as factors responsible for
the difference in spinal cord events relative to TEVAR.
Also, the location and length of endografts necessary to
successfully treat focal transection lesions may influence the
risk of spinal cord ischemia.
Endografts are usually placed in the distal arch or proximal
descending aorta, or both, and are relatively short (mean
device length in this study, 127 mm) compared with what is
commonly required to bridge more extensive degenerative
aneurysms.20-24 Thus, coverage of critical intercostal arteries
that contribute perfusion to the spinal cord, those between the
T6 and L1 vertebral levels, is rarely required. In transection
cases, the deployment of short endografts, usually15 cm, in
the proximal descending aorta most likely influences the risk
of paraplegia/paraparesis and may account for lower proce-
dural rates of spinal cord ischemic events relative to those
associated with open repair of transection and TEVAR treat-
ment of more extensive nontraumatic lesions.
Among the limitations to this data set are that this is a
relatively small number of patients compared with published
meta-analyses. However, this data set does have detailed re-
cords and follow-up through 1 year. There is an unusually low
and unexplainable lack of secondary interventions. Full radio-
logic imaging information was not included beyond identify-
ing complications or need for secondary interventions.
In addition, there were slightly varying eligibility criteria,
but all trials addressed the applications of endografts to tho-
racic pathologies. Given the purpose of this data set is proof of
principle to serve as 30 day point estimate for mortality and
potentially an objective performance criteria, data on individ-
ual endografts were not collected. Despite these limitations,
this is a valuable data set for this patient population.
CONCLUSIONS
TEVAR placement for the management of patients with
traumatic aortic injury is associated with a cumulative 1-year
survival of 85.6%  5.2%. Most cases treated were due to
motor vehicle accident and associated with multiple coexisting
injuries. Approximately three-quarters of the deaths occurred
within 30 days. Although the relatively low adverse event and
major adverse event rates are consistent with what is antici-
pated in an otherwise healthy population, routine imaging was
not obtained. Future device and procedural developments
may facilitate improved outcomes in the future.
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